Headlines
Women-focused weight-loss startup SheMed raises $50 million at $1 billion valuation
Published by Global Banking and Finance Review
Posted on October 23, 2025
2 min readLast updated: January 21, 2026
Home > Headlines > Women-focused weight-loss startup SheMed raises $50 million at $1 billion valuation
Quick Summary
SheMed, a London-based startup, raised $50M, reaching a $1B valuation. It offers personalized weight-loss plans for women, amid rising demand for GLP-1 drugs in the UK.
SheMed Secures $50 Million Funding, Achieves $1 Billion Valuation
(Reuters) -London-based telehealth startup SheMed said on Thursday it raised $50 million in a Series A round, valuing the company at $1 billion, as demand for weight-loss drugs Wegovy and Mounjaro grows in Britain.
Demand for Novo Nordisk's Wegovy and Eli Lilly's Mounjaro has surged in the United Kingdom, with patients often facing longer waits for treatment through the National Health Service.
Founded in April 2024 by sisters Olivia and Chloe Ferro, SheMed designs weight-loss and wellness programs for women. The startup has signed up more than 60,000 members in under a year, offering personalized plans that pair medication with health screenings and ongoing support.
"The demand for SheMed's services has been extraordinary," said Olivia Ferro, the company's chief executive.
Women make up a majority of patients that use GLP-1 drugs, the class of treatments to which Mounjaro and Wegovy belong.
Unlike telehealth rivals that rely on self-reported body mass index, SheMed uses blood tests to determine eligibility for GLP-1 treatment plans.
Most recent sign-ups have chosen Wegovy over Mounjaro after a Lilly price increase in the UK, a company spokesperson said, and some existing Mounjaro users have switched to Wegovy.
SheMed said it will use the new funding to expand across the United Kingdom, back research and other initiatives, and improve access to personalised care for women.
The company plans to publish a study later this month using data from enrolled women to assess how GLP-1 medicines affect hormonal and metabolic health beyond weight loss.
(Reporting by Unnamalai L in Bengaluru; Editing by Krishna Chandra Eluri and Tasim Zahid)
Key Takeaways
- •SheMed raised $50 million in Series A funding.
- •The company is valued at $1 billion.
- •Demand for weight-loss drugs is rising in the UK.
- •SheMed offers personalized health plans for women.
- •Expansion plans include research and improved access.
Frequently Asked Questions about Women-focused weight-loss startup SheMed raises $50 million at $1 billion valuation
1What is a Series A funding round?
A Series A funding round is the first significant round of investment in a startup, typically following seed funding. It is aimed at scaling the business and is often led by venture capital firms.
2What is a valuation?
A valuation is the process of determining the current worth of an asset or a company. It is often used in investment and financial analysis to assess the value of a business before investment or acquisition.
